
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Looking for broad exposure to the Industrials - Water segment of the equity market? You should consider the Invesco Water Resources ETF (PHO), a passively managed exchange traded fund launched on December 6, 2005.

The Invesco Water Resources ETF has underperformed both the S&P 500 and several competing water ETFs since late 2024. PHO's portfolio is light on water exposure, with top holdings like Waters, Roper, and Ecolab being only modestly linked to the theme. PHO could outperform if the AI CAPEX boom fades and other industries like software and life sciences rebound, given its portfolio tilt.

/PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix/Cysview revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3

/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication in 'The Journal of Medical Economics' of a novel health

/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication in 'The Journal of Medical Economics' of a novel health

The Invesco Water Resources ETF (PHO) was launched on 12/06/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Industrials ETFs category of the market.

Launched on December 6, 2005, the Invesco Water Resources ETF (PHO) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Water segment of the equity market.

Invesco Water Resources ETF (NASDAQ: PHO - Get Free Report) shares passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $72.01 and traded as low as $65.87. Invesco Water Resources ETF shares last traded at $66.53, with a volume of 76,520 shares. Invesco Water

/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of

/PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of
